Free Articles Online » Fitness Equipment

Global Industry trends that can offer Growth opportunities for MRI Market

bharatbookseo — Mon, 27 Sep 2010 09:18:16 +0000

Medical Magnetic Resonance Imaging (MRI): Technologies and Global Markets

The report examines the MRI equipment industry in general, the types of technology currently in use as well as future applications, and regulatory influences. The industry structure section discusses the most active suppliers with regard to relative market share, marketing strengths, and forces that promote or hamper growth of technologies. The technology sections detail historical, current, and projected (2010 through 2015) market values. ( http://www.bharatbook.com/detail.asp?id=150174&rt=Medical-Magnetic-Resonance-Imaging-MRITechnologies-and-Global-Markets.html )

Highlights

* In the U.S., recent reimbursement changes and the economic downturn have called the expanding use of MRI scanning into question. The North American market is worth $2.3 billion in 2010 and is expected to increase at a 4.4% compound annual growth rate (CAGR) to reach $2.9 billion in 2015.
* Europe ranks with the U.S. as one of the most developed MRI markets. Expanding applications in the neurologic, cardiac, and breast MRI areas should drive the EU market. This sector is estimated at $1.2 billion in 2010 and is expected to increase at a 10% compound annual growth rate (CAGR) to reach $1.9 billion in 2015.
* Japan remains an early adopter of newer MRI equipment, making it a prime opportunity for newer 3T equipment. This market is valued at $1 billion in 2010 and should reach $1.3 billion in 2015, a compound annual growth rate (CAGR) of 4.3%.

STUDY GOALS AND OBJECTIVES

The goal of this study is to describe and discuss changes in the global MRI market. This report is designed to achieve the following objectives:
To describe the trends and developments for each type of MRI technology and how each is meant to satisfy the needs of manufacturers.
To analyze market and driving forces to determine the market size for the technologies and pinpoint target applications.
To examine the MRI business in terms of specific companies and their position in the market.
The report is designed to appeal to many different readers including venture capitalists interested in exploring commercialization opportunities, marketing and management individuals within the industry, and even the casual reader who desires to understand how market pressures and technology interact in this industry.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=150174&rt=Medical-Magnetic-Resonance-Imaging-MRITechnologies-and-Global-Markets.html

Related Reports

Medical Imaging Markets: MRI (Magnetic Resonance Imaging) and Ultrasound
http://www.bharatbook.com/detail.asp?id=106693&rt=Medical-Imaging-Markets-MRI-Magnetic-Resonance-Imagingand-Ultrasound.html

Global Medical Imaging Equipment Market 2008-2012
http://www.bharatbook.com/detail.asp?id=114186&rt=Global-Medical-Imaging-Equipment-Market-2008-2012.html

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Email: info@bharatbook.com
Website: www.bharatbook.com
Follow us on twitter: http://twitter.com/3bbharatbook
Please visit our blog at http://bharatbookseo.blogsome.com

Click on pen to

Molecular Diagnostics is the fastest growing segment in the In Vitro Diagnostics market

bharatbookseo — Wed, 22 Sep 2010 11:32:14 +0000

Global In Vitro Diagnostics (IVD) Market Trends and Future Forecast (2009 – 2014)

The report provides market landscape, competitive landscape and market trends information on ten market categories including Molecular Diagnostics, Clinical Chemistry, Hematology, Immunoassay, Point of Care Testing, Microbiology, Histology/Cytology, Flow Cytometry, Blood Screening Typing, and Coagulation. The report provides comprehensive information on the key trends affecting these categories, and key analytical insight on the market dynamics. The report reviews the competitive landscape in terms of mergers and acquisitions, licensing, pipeline products and new technology offerings. The report also analyses past present and future forecast of USA, Japan, Europe, India, China and Taiwan IVD market. ( http://www.bharatbook.com/detail.asp?id=150732&rt=Global-In-Vitro-Diagnostics-IVDMarket-Trends-and-Future-Forecast-2009-2014.html )

The report has been researched at source globally and features latest available data covering:

• Ten IVD sub-segment past, present and future forecast market share
• Six countries (USA, Japan, Europe, India, China, Taiwan) past, present, future prospects in the IVD market
• Top eight companies (Sysmex, BioMerieux, OCD (J&J), Beckman Coulter, BD, Abbott Diagnostics, Siemens & Roche) IVD market share in 2009
• Top ten Merger & Acquisition deals in 2008 and 2009
• Licensing by ten IVD players
• Review of International In Vitro Diagnostics Regulations
• Key drivers of growth in the global IVD market
• Key challenges faces by IVD market in the coming years

Research Highlights

• Globally, In Vitro Diagnostics market will cross US$ 60 Billion by 2014
• Point of Care Testing dominates the In Vitro Diagnostics market with more than 30% market share in 2009
• Molecular Diagnostics is the fastest growing segment in the In Vitro Diagnostics market, its market share will reach approximately 18% by 2014
• In 2009 Roche, Siemens and Abbott Diagnostics together controls 42% market share in In Vitro Diagnostics, Roche controls the highest market share
• After Point of Care Testing, Immunoassay is the second largest market with a market of more than US$ 7 Billion in 2009
• Europe with more than US$ 10 Billion is the second largest In Vitro Diagnostics Market in 2009
• 51 Mergers & Acquisitions taken place in 2008 compared to 84 deals in 2007
• 18 In-Licensing deals were announced in 2008 compared to 27 in 2007
• By 2009 there were 12 countries with more than 10 Million people aged 60 or over
• Third Wave Technologies (TWT) was acquired by Hologic to grow its existing women’s health and diagnostics business was the best deal in 2008
• In 2009, Beckman Coulter acquired the diagnostic systems part of Olympus’s life sciences to broaden its clinical chemistry offering, especially in the ultra-high throughput setting.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=150732&rt=Global-In-Vitro-Diagnostics-IVDMarket-Trends-and-Future-Forecast-2009-2014.html

Related Reports

The Future of the In-Vitro Diagnostics Market to 2016 – Increasing Diagnostic Procedures Drive Demand

http://www.bharatbook.com/detail.asp?id=130193&rt=The-Future-of-the-In-Vitro-Diagnostics-Market-to-2016-Increasing-Diagnostic-Procedures-Drive-Demand.html

Global In Vitro Diagnostics Market Analysis and Forecasts to 2015

http://www.bharatbook.com/detail.asp?id=127320&rt=Global-In-Vitro-Diagnostics-Market-Analysis-and-Forecasts-to-2015.html

Click on pen to

Bulk drugs Market structure and its Investments

bharatbookseo — Fri, 17 Sep 2010 10:54:22 +0000

Bulk drugs

· Bulk drugs or active pharmaceutical ingredients (API) are the raw materials for manufacturing formulations or finished dosage forms of drugs.
· As the Indian bulk drug industry is primarily export-oriented, its future prospects largely hinges on its ability to tap the opportunity arising both in the regulated and semi-regulated market.
· The opportunities in the regulated market (outsourcing/supply of bulk drugs) are expected to emerge both for manufacturing on-patent and off-patent drugs. This is in the wake of the extensive cost-reduction initiatives of global pharmaceutical companies in a bid to improve profitability and impending genericisation respectively. ( http://www.bharatbook.com/detail.asp?id=149805&rt=Bulk-drugs.html )

Market size and structure

· Bulk drugs exports account for around 80-90 per cent of the total production.
· Bulk drugs export in terms of revenue was estimated to be around $5.9 billion in 2008-09.
· India’s share in the total global bulk drug market has grown from around 3.5 – 4.0 per cent in 2003-04 to 6.5 – 7.0 per cent in 2008-09.
· Rising pressure on innovator companies to re-align costs and ensure higher scale of business at improved profitability levels has significantly enhanced supply of bulk drugs to regulated markets. Bulk drugs export to the regulated market have surged from an estimated $0.5 billion in 2003-04 to an estimated $3.1 billion in 2008-09 on the strength of growing outsourcing/supply of bulk drugs for manufacturing off-patent drugs.
· Share of bulk drug exports to regulated markets in total bulk drug exports has increased significantly from around 35 per cent in 2003-04 to nearly 54 per cent in 2008-09.
· Also bulk drugs supplied for manufacturing on-patent drugs is gaining momentum with its share rising from 1.7 per cent in 2003-04 to around 9.3 per cent in 2008-09.

Investment outlook

· The bulk drug industry is not capital intensive. However, relatively higher capital commitment is required to set up manufacturing facilities conforming to several international regulatory requirements such as approval of the plant by United States Food and Drug Administration (US FDA), cGMP compliance etc.

· Investments are expected to maintain its pace in tandem with the growth momentum expected in the bulk drug industry in the next 5 years. The sector is likely to witness investments to the tune of $ 5-7 billion in the next five years. With a continuing focus on exports, substantial investments will be directed in setting up plants in compliance with international regulatory standards.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=149805&rt=Bulk-drugs.html

Global Markets for Orphan Drugs
http://www.bharatbook.com/detail.asp?id=145116&rt=Global-Markets-for-Orphan-Drugs.html

Click on pen to

Growth drivers of the Biopharmaceuticals market

bharatbookseo — Fri, 17 Sep 2010 06:38:18 +0000

Biopharmaceuticals

Biopharmaceuticals are drugs developed through the application of biotechnology on living organisms intended for the treatment of diseases. These are generally obtained by genetically manipulating the genes that are responsible for the occurrence of a particular disease. ( http://www.bharatbook.com/detail.asp?id=149802&rt=Biopharmaceuticals.html )

* Indian biopharmaceuticals market is primarily generic with a majority of the Indian companies supplying vaccines (preventive and therapeutic), and a few selling biosimilars in the semi-regulated market.

* Indian players are expected to tap the impending biosimilars opportunity in the regulated market while retaining a stable foothold in the semi-regulated market.

Key chapters :

Sections
Key highlights 1
Segmental definition 2
Structure 4
- Industry structure 4
- Market size and structure 5
- Growth drivers of the industry 6
- Revenue model 8
- Cost structure 11
- Industry structure 11
- Porter’s five competitive forces model 12
- Regulatory environment 13
- Drug development process 16
Conduct 19
- Player Profiles 19
Performance 29
- Demand Review 29
- Demand outlook 29
- Cost and margins 30
- Financial performance 31
Investment opportunity 32
- Opportunities and risks 32
- Risks and structural weaknesses 33
- Investments and financing 33
- Mergers and acquisition 34
- Glossary 35
- Fact Sheet 35

Boxes
Structure 4
- Key elements of the National Biotechnology Development Strategy 16
Performance 29
- Indian biopharmaceutical market – Demand methodology 30

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=149802&rt=Biopharmaceuticals.html

Related Reports

Top 10 Biotechnology Companies – SWOT Analysis, Competitive Benchmarking, Financial Analysis and R&D Pipeline
http://www.bharatbook.com/detail.asp?id=130195&rt=Top-10-Biotechnology-Companies-SWOT-Analysis-Competitive-Benchmarking-Financial-Analysis-and-R-D-Pipeline.html

Biotechnology: Global Industry Guide
http://www.bharatbook.com/detail.asp?id=132164&rt=Biotechnology-Global-Industry-Guide.html

Click on pen to

Profiles of key companies operating within the South Africa In Vitro Diagnostics market

bharatbookseo — Tue, 14 Sep 2010 04:43:59 +0000

South Africa In Vitro Diagnostics Market Outlook to 2016

The report provides value (USD million), volume (units) and average price (USD) data for each segment and sub-segment within seven market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available. ( http://www.bharatbook.com/detail.asp?id=145455&rt=South-Africa-In-Vitro-Diagnostics-Market-Outlook-to-2016.html )

Scope

- Market size and company share data for In Vitro Diagnostics (IVD) market categories – clinical chemistry, genetic testing, histology and cytology, immuno chemistry, infectious immunology, microbiology culture, and haematology.
- Annualized market revenues (USD million), volume (units) and average price (USD) data for each of the segments and sub-segments within seven market categories. Data from 2002 to 2009, forecast forward for 7 years to 2016.
- 2009 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the South Africa In Vitro Diagnostics (IVD) market.
- Key players covered include Roche, Siemens Healthcare, Abbott, Beckman Coulter, Biomerieux, Ortho-Clinical Diagnostics, and Becton, Dickinson.

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the South Africa In Vitro Diagnostics (IVD) competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

To know more and to buy a copy of your report feel free to visit : http://www.bharatbook.com/detail.asp?id=145455&rt=South-Africa-In-Vitro-Diagnostics-Market-Outlook-to-2016.html

Related Reports :

Global In Vitro Diagnostics Investment Opportunities Analysis and Forecasts
http://www.bharatbook.com/detail.asp?id=98952&rt=Global-In-Vitro-Diagnostics-Investment-Opportunities-Analysis-and-Forecasts.html

The Top Ten Global In-Vitro Diagnostics Companies: Positioning, performance and SWOT analyses
http://www.bharatbook.com/detail.asp?id=126595&rt=The-Top-Ten-Global-In-Vitro-Diagnostics-Companies-Positioning-performance-and-SWOT-analyses.html

Click on pen to

Global Molecular Diagnostics Market: Opportunities & Future Forecast

bharatbookseo — Tue, 07 Sep 2010 11:20:26 +0000

Global Molecular Diagnostics Market: Opportunities & Future Forecast

“Global Molecular Diagnostics Market: Opportunities & Future Forecast” analysis the global molecular diagnostics market. This research report provides the global molecular diagnostics industry past present and future scenario. The specific clinical segments like Infectious Disease Testing Market, ID/forensics Market, Tissue Typing Market, Oncology Market, Food Testing Market, Genetic Testing Market and Pharmacogenomics Market past, present and future scenario has been analyzed in this report. (http://www.bharatbook.com/detail.asp?id=104390&rt=Global-Molecular-Diagnostics-Market-Opportunities-Future-Forecast.html) The report provides separate comprehensive past, present and future forecast of molecular diagnostics market on country level as well. Countries covered in the report are: US, Europe and India.

Market Overview

Based on its exceptional ability to accurately detect the primary cause of disease, molecular diagnostics has emerged as the fastest growing segment of the in vitro diagnostics (IVD) industry. Growing with a CAGR of 19 percent global molecular diagnostics market is expected to reach US$ 7 Billion by 2011. The infectious disease was having the biggest market share of 70 percent but gradually its share will decline to 50 percent. The future growth is expected to come from Oncology Testing, Genetic Testing and Pharmacogenomics Testing.

Geographically, the US and European markets are the most advanced in terms of adoption of molecular testing and make up the majority of the existing market. However Indian molecular diagnostics market is also catching up fast and future growth is expected from these markets when US and European market will mature. Key player wise molecular diagnostics market is dominated by big companies such as Roche Diagnostics, Gen-Probe, Siemens Healthcare Diagnostics Inc. and Abbott Laboratories which are active in every segment of the clinical diagnostics market. They have broader product portfolios, which can address the needs of any kind of clinical laboratories. However, their leadership is likely to be challenged by the emergence of a new breed of players who target growth areas such as oncology and pharmacogenomics.

Report Forecasts

• What will be the global molecular diagnostics market in 2011?
• What will be the molecular diagnostics market of Europe, India in 2011 and US in 2012?
• What will be the market of Infectious Disease Testing in 2011?
• What will be the market of ID/forensics Market in 2011?
• What will be the market of Tissue Typing Market in 2011?
• What will be the market of Oncology Market in 2011?
• What will be the market of Food Testing Market in 2011?
• What will be the market of Genetic Testing Market in 2011?
• What will be the market of Pharmacogenomics Market in 2011?

Research Highlights

• Global molecular diagnostics market is expected to reach the figure of US$ 7 Billion by 2011.
• US molecular diagnostics market is expected to cross the US$ 4 Billion by 2012.
• European molecular diagnostics market is expected to cross US 1 Billion by 2012.
• India molecular diagnostics market is expected to cross INR 1 Billion by 2011.
• United States and Europe together holds more than 75 percent of molecular diagnostics market in 2008.
• Infectious disease has the highest percentage of market share in 2008 but its share will decline in future.

For more information kindly visit :
http://www.bharatbook.com/detail.asp?id=104390&rt=Global-Molecular-Diagnostics-Market-Opportunities-Future-Forecast.html

Related Reports

Future of Molecular Diagnostics: Innovative technologies driving market opportunities in personalized medicine
http://www.bharatbook.com/detail.asp?id=144695&rt=The-Future-of-Molecular-Diagnostics-Innovative-technologies-driving-market-opportunities-in-personalized-medicine.html

Molecular Diagnostics – Technologies, Markets and Companies
http://www.bharatbook.com/detail.asp?id=145783&rt=Molecular-Diagnostics-Technologies-Markets-and-Companies.html

Click on pen to

Insulin Delivery Devices Market Analysis and Future Forecast

bharatbookseo — Tue, 07 Sep 2010 07:36:17 +0000

Insulin Delivery Devices Market Analysis and Future Forecast

Insulin Delivery Devices Market Analysis and Future Forecast gives a detailed analysis on the global insulin market. The report analyses and forecast on market size of different insulin delivery devices i.e. global insulin pen market, insulin pump market, insulin syringe market and insulin jet injector market. The report investigates insulin delivery devices market on the country level as well.( http://www.bharatbook.com/detail.asp?id=99014&rt=Insulin-Delivery-Devices-Market-Analysis-and-Future-Forecast.html ) Countries covered in the report are: for Insulin pen market – US, Europe, India and Japan; Insulin pump market – US and India; Insulin syringe market – US and India; Insulin jet injector market – US.

After analyzing data from different sources we have come to conclusion that insulin pen is the most preferred mode of injecting insulin globally. Though the insulin syringes are still popular it is ceding market share rapidly to insulin pen and pump. Currently insulin pen leads the market segment but in the future insulin pump will dominate the market, as there is lot of R&D going on for improving it. Insulin pen are popular in Europe and Japan while insulin pumps are gaining popularity in US, fast replacing the dominance of insulin syringe in the market. Even developing countries like India are adapting the insulin pen for its growth going forward. Among future devices oral insulin and implantable insulin pump have bright future.

Key Questions Answered in this Report

• What is the present and future market size of insulin pen, insulin pump, insulin syringe and insulin jet injector globally?
• What is insulin delivery devices market in 2007 and 2014 for Europe?
• What is the present and future forecast of US, Europe and India insulin pen market?
• What is the market share of companies in global pump market?
• What is the present and future forecast of US insulin pump market?
• Which company will control the US pump market in future?
• What is oral insulin market of US?
• What is the future of insulin patch, oral insulin and implantable insulin pump?

Report Highlights

• Globally by 2007 insulin pen controls more than 50 percent of market share in insulin delivery devices market.
• In 2006 insulin pen market share in Europe and Japan was more than 85 percent.
• Global insulin pump and disposables market is expected to grow with a double digit figure.
• By 2009 companies Disetronic and MiniMed together are expected to control more than 70 percent of the insulin pump market globally.
• US insulin pen is forecasted to grow at a CAGR of 11.96 percent from 2006 to 2010.
• US insulin syringe market is expected to show a negative CAGR of -0.7 from 2007 to 2009.
• US insulin pump market is expected to grow with a CAGR of 11.8 percent from 2002 to 2009.
• European insulin pen market is expected to grow further but its market share is expected to decline from 89.7 percent in 2007 to 70.6 percent in 2014.

Key Company Profiles

This section provides business overview and key financial information of the companies listed:
Novo Nordisk A/S, Sanofi-Aventis, Becton, Dickinson and Company, GlaxoSmithKline plc, Amylin Pharmaceuticals, Inc., Merck & Co., Inc., Eli Lilly and Company.

Data Sources

Information and data in this report has been collected from various printable and non-pintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.

For more information kindly visit :

http://www.bharatbook.com/detail.asp?id=99014&rt=Insulin-Delivery-Devices-Market-Analysis-and-Future-Forecast.html

Related Reports

Insulin Pumps Pipeline Technology And Market Forecasts To 2015

http://www.bharatbook.com/detail.asp?id=89239&rt=Insulin-Pumps-Pipeline-Technology-And-Market-Forecasts-To-2015.html

Insulin Delivery Systems Market Analysis

http://www.bharatbook.com/detail.asp?id=104778&rt=Insulin-Delivery-Systems-Market-Analysis.html

Click on pen to

Clinical Trial Recruitment Strategies.

bharatbookseo — Tue, 07 Sep 2010 06:17:44 +0000

Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
The recruitment of patients for clinical trials is an essential part of the complex and inherently risky R&D process for pharmaceuticals. ( http://www.bharatbook.com/detail.asp?id=132644&rt=Clinical-Trial-Recruitment-Strategies-Optimizing-patient-recruitment-and-retention-in-late-stage-clinical-trials.html ) Operationally, patient recruitment involves targeting the right patients with the right messages and retaining enrolled patients with effective ‘customer service’. However, patient recruitment also impacts on crucial strategic objectives involving the planning of trial protocols and the management of risk.

One of most significant challenges associated with clinical trial recruitment is managing the relationships between the different partners who each play an essential role in recruiting and retaining patients. It is not unusual for late stage clinical trial recruitment to involve a partnership between the trial sponsor, a dedicated contract research organization, a patient recruitment agency, a communications agency and clinical investigators at the trial sites themselves. A significant amount of planning and coordination is required to bring each party together and deliver on their respective objectives.

As a result of the critical importance of patient recruitment, and the inherent complexity of dealing with agency and clinical partners, as well as managing the expectations of patients, it has become a distinct area of potential competitive advantage. In the same way that alliance management or sales force deployment have helped some companies to develop competitive advantages, those companies best able to deliver on their patient recruitment and retention objectives will enjoy a comparative advantage in late stage clinical trial delivery, completing trials with greater levels of cost-efficiency, timeliness and success.

Key features of this report

• Evaluation of patient recruitment: a detailed analysis as to the important role played by patient recruitment within the broader clinical trial program and beyond
• Contextual trend analysis: a comprehensive trend analysis setting the context for patient recruitment efforts across the varying parameters associated with clinical trials
• Key performance benchmarks: a detailed set of patient recruitment benchmark targets based on the most up to date clinical trial data available

Scope of this report

• Understand and communicate the full value of effective patient recruitment as an essential part of the wider clinical trial function
• Establish a contextual framework for patient recruitment planning and program management based on the latest trends in trial design and patient recruitment performance
• Set useful performance benchmarks to guide recruitment efforts and identify the key drivers of benchmarked success in order to keep recruitment projects on track

Key Market Issues

(1) Competition for patients
The number and average size of late stage clinical trials has increase significantly over the last 5 years, resulting in a significant increase in the competition to recruit patients

(2) Trial site selection
As the competition for patients has increased, the average number of trial sites used for each trial has also increased, putting extended pressure on the important decision of site selection

(3) Protocol design and inclusion/exclusion criteria
The impact of patient recruitment planning on the design of trial protocols and eventual inclusion/exclusion criteria is leading to a more clear incorporation of the ‘recruitability’ measure for patients when designing trials

Key findings from this report

(1) In the same way that alliance management or sales force deployment have helped some companies to develop competitive advantages, those companies best able to deliver on their patient recruitment and retention objectives will enjoy a comparative advantage in late stage clinical trial delivery, completing trials with greater levels of cost-efficiency, timeliness and success. (chapter 1)
(2) Although trial lifecycles appear to be shortening, the rate of successful completion for late stage trials is also falling. Patient enrollment levels are increasing, which in turn has led to a significant rise in the average number of trial sites involved in each trial. The requirement to increase trial recruitment numbers is compounded by an increase in inclusion/exclusion criteria which narrows the field of potential trial candidates. (chapter 2)
(3) Global trial programs have the longest average recruitment window, despite having the lowest recruitment period per enrollee amongst other trial locations. Phase III trials conducted outside North America are associated with the longest recruitment and relative recruitment periods. Global trial programs are associated with the longest completion delays, while European trials result in the longest delays relative to the number of enrollees. (chapter 3)

Key questions answered

• How important is patient recruitment within the context of the clinical trial process and its role in the overall success in the pharmaceutical industry?
• What are the key trends in the number, length, completion failure rate and size of clinical trials and how do these trends impact on patient recruitment?
• What are the key benchmarks tracking the performance of recently completed trials by length of recruitment and any subequent delay?

For more information kindly visit
http://www.bharatbook.com/detail.asp?id=132644&rt=Clinical-Trial-Recruitment-Strategies-Optimizing-patient-recruitment-and-retention-in-late-stage-clinical-trials.html

http://www.bharatbook.com/detail.asp?id=132646&rt=The-Future-of-R-D-Outsourcing-Investigating-development-hurdles-key-challenges-strategies-to-optimize-CRO-relationships.html

http://www.bharatbook.com/detail.asp?id=133969&rt=Opportunities-in-Emerging-Pharma-Markets-Strategies-for-optimizing-growth-in-key-regions-and-therapeutic-areas.html

OR Contact us at

Click on pen to

Global Diabetes Market Trends & Future Forecast

bharatbookseo — Mon, 06 Sep 2010 10:34:36 +0000

HTML clipboardGlobal Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1

“Global Diabetes Market Trends & Future Forecast – Diabetes Drug (Anti-Diabetic Drug), Insulin, DPP-IV, GLP-1” report provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally, country specific and features latest available data covering: ( http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html )

• Global Diabetes Drug, Insulin, DPP-IV, GLP-1 Agonists Market and Future Forecast
• Region wise Diabetes, Impaired Glucose Tolerance (IGT) Population and Prevalence
• Region wise Diabetes Health Expenditure and Mortality
• Top 10 Countries Diabetes Population and Future Forecast
• Top 5 Countries Diabetes Drug Market and Future Forecast
• Top 7 Countries Insulin Market and Future Forecast
• Top 6 Diabetes Drug Brands ( Avandia, Actos, Amaryl, Avandamet, Prandin/Novonorm, Starlix) data of Past, Present and Future Market
• Top 9 Insulin Brands (Novomix, Novorapid, Levemir, Degludec, Degludecplus, Humalog, Humulin, Apidra, Lantus) data of Past, Present and Future Market
• Top 4 DPP-IV Inhibitors (Januvia, Onglyza, Alogliptin, Galvus) data of Past, Present and Future Market
• Top 5 GLP-1 Agonists (Byetta, Victoza, Exenatide LAR, Syncria, Taspoglutide) data of Past, Present and Future Market

Research Highlights

• USA controls more than 50% of the total Diabetes Drug market share in 2009
• Global Insulin Market is estimated to reach around US$ 17 Billion by 2013
• China will have the second highest Insulin market share by 2012 replacing Germany
• DPP-IV Inhibitors is predicted to be more than US$ 5 Billion market by 2015
• GLP-1 Agonists, market is forecasted to cross US$ 6 Billion mark by 2015
• Novorapid is the blockbuster Insulin of Novo Nordisk it is expected to cross US$ 3 Billion by 2015.
• Yet to launched Degludec and DegludecPlus is expected to be blockbuster Insulin and cross US$ 4 Billion and US$ 6 Billion respectively by 2030.
• Januvia is proving a blockbuster of DPP – IV Inhibitors segment expected to be more than US$ 4 Billion by 2017
• Last year launched Victoza and yet to be launched Exenatide LAR is going to be blockbuster GLP-1 Agonists
• China diabetes drug market has crossed the figure of Yuan 10 Billion by 2009
• Japan Insulin market is expected to be more than US$ 1 Billion by 2010

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=144402&rt=Global-Diabetes-Market-Trends-Future-Forecast-Diabetes-Drug-Anti-Diabetic-DrugInsulin-DPP-IV-GLP-1.html

Related Reports

India Diabetes Care Devices Market Outlook to 2016
http://www.bharatbook.com/detail.asp?id=94991&rt=India-Diabetes-Care-Devices-Market-Outlook-to-2016.html

The Future of the Diabetes Care Devices Market to 2016 – The Key Demand Drivers Remain Intact
http://www.bharatbook.com/detail.asp?id=130194&rt=The-Future-of-the-Diabetes-Care-Devices-Market-to-2016-The-Key-Demand-Drivers-Remain-Intact.html

Click on pen to

Innovations and Opportunities in Therapeutic Vaccines

bharatbookseo — Mon, 06 Sep 2010 10:18:48 +0000

Innovations and Opportunities in Therapeutic Vaccines: Technology platforms, key players, and early pipeline candidates

Therapeutic vaccines promise a new wave of highly potent and highly specific therapeutic agents designed to work in harmony with patients’ own immune systems. Recent advances in the understanding of the human immune system and in technical capabilities have allowed vaccines to move beyond pre-emptive (prophylactic) immunization and into treatment of established diseases. In April 2010, Dendreon’s Provenge became the first ever cancer vaccine to be approved by the US Food and Drug Administration (FDA), overcoming skepticism in the investment community and paving the way for a new generation of biological therapies. ( http://www.bharatbook.com/detail.asp?id=146417&rt=Innovations-and-Opportunities-in-Therapeutic-Vaccines-Technology-platforms-key-players-and-early-pipeline-candidates.html )

This report explains what therapeutic vaccines are, how they work, and why drug developers around the world are using this approach to address everything from allergies to literally every kind of cancer. More than 70 new proprietary technologies are named and explained, with details of licensing deals and intellectual property positions.

The newest wave of drug candidates based on these technologies can be seen in more than 130 early pipeline candidates, each based on a commercial company or research institute known to have carried out preclinical and/or Phase I trials of at least one therapeutic vaccine candidate in the past year. By way of background, later stage candidates being developed by the same companies are also discussed. In total, more than 270 therapeutic vaccine candidates are identified in this report. Finally, prospects and challenges for the future of this field are discussed, with opinions from around 20 prominent industry leaders and academic researchers.

Key features of this report

• ‘Beginners guide’ to vaccines and the human immune system, illustrated with original full-color diagrams, to show the potential challenges and benefits of therapeutic vaccination.
• More than 70 descriptions of proprietary technologies currently in use around the world to design, produce and administer therapeutic vaccines.
• A comprehensive guide to companies around the world that are currently developing brand new therapeutic vaccines (i.e. candidates in preclinical or Phase I clinical trials).
• Details of more than 270 specific vaccine candidates, in development by around 120 different companies and research institutes.
• Expert opinions on the opportunities, challenges and future trends in the therapeutic vaccine field from around 20 industry leaders and academic researchers, over a dozen of whom were contacted directly and interviewed for this report.

For more information kindly visit : http://www.bharatbook.com/detail.asp?id=146417&rt=Innovations-and-Opportunities-in-Therapeutic-Vaccines-Technology-platforms-key-players-and-early-pipeline-candidates.html

Related Reports

Therapeutic Vaccines: The Global Market
http://www.bharatbook.com/detail.asp?id=145063&rt=Therapeutic-Vaccines-The-Global-Market.html

World Outlook for Therapeutic Vaccines
http://www.bharatbook.com/detail.asp?id=95679&rt=World-Outlook-for-Therapeutic-Vaccines.html

Click on pen to